These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

769 related items for PubMed ID: 28411381

  • 1. PBX3 is essential for leukemia stem cell maintenance in MLL-rearranged leukemia.
    Guo H, Chu Y, Wang L, Chen X, Chen Y, Cheng H, Zhang L, Zhou Y, Yang FC, Cheng T, Xu M, Zhang X, Zhou J, Yuan W.
    Int J Cancer; 2017 Jul 15; 141(2):324-335. PubMed ID: 28411381
    [Abstract] [Full Text] [Related]

  • 2. PBX3 and MEIS1 Cooperate in Hematopoietic Cells to Drive Acute Myeloid Leukemias Characterized by a Core Transcriptome of the MLL-Rearranged Disease.
    Li Z, Chen P, Su R, Hu C, Li Y, Elkahloun AG, Zuo Z, Gurbuxani S, Arnovitz S, Weng H, Wang Y, Li S, Huang H, Neilly MB, Wang GG, Jiang X, Liu PP, Jin J, Chen J.
    Cancer Res; 2016 Feb 01; 76(3):619-29. PubMed ID: 26747896
    [Abstract] [Full Text] [Related]

  • 3. PBX3 is an important cofactor of HOXA9 in leukemogenesis.
    Li Z, Zhang Z, Li Y, Arnovitz S, Chen P, Huang H, Jiang X, Hong GM, Kunjamma RB, Ren H, He C, Wang CZ, Elkahloun AG, Valk PJ, Döhner K, Neilly MB, Bullinger L, Delwel R, Löwenberg B, Liu PP, Morgan R, Rowley JD, Yuan CS, Chen J.
    Blood; 2013 Feb 21; 121(8):1422-31. PubMed ID: 23264595
    [Abstract] [Full Text] [Related]

  • 4. Meis1 is an essential and rate-limiting regulator of MLL leukemia stem cell potential.
    Wong P, Iwasaki M, Somervaille TC, So CW, Cleary ML.
    Genes Dev; 2007 Nov 01; 21(21):2762-74. PubMed ID: 17942707
    [Abstract] [Full Text] [Related]

  • 5. SUV39H1 regulates the progression of MLL-AF9-induced acute myeloid leukemia.
    Chu Y, Chen Y, Guo H, Li M, Wang B, Shi D, Cheng X, Guan J, Wang X, Xue C, Cheng T, Shi J, Yuan W.
    Oncogene; 2020 Dec 01; 39(50):7239-7252. PubMed ID: 33037410
    [Abstract] [Full Text] [Related]

  • 6. Six1 regulates leukemia stem cell maintenance in acute myeloid leukemia.
    Chu Y, Chen Y, Li M, Shi D, Wang B, Lian Y, Cheng X, Wang X, Xu M, Cheng T, Shi J, Yuan W.
    Cancer Sci; 2019 Jul 01; 110(7):2200-2210. PubMed ID: 31050834
    [Abstract] [Full Text] [Related]

  • 7. HOXA9 is required for survival in human MLL-rearranged acute leukemias.
    Faber J, Krivtsov AV, Stubbs MC, Wright R, Davis TN, van den Heuvel-Eibrink M, Zwaan CM, Kung AL, Armstrong SA.
    Blood; 2009 Mar 12; 113(11):2375-85. PubMed ID: 19056693
    [Abstract] [Full Text] [Related]

  • 8. Inactivation of PBX3 and HOXA9 by down-regulating H3K79 methylation represses NPM1-mutated leukemic cell survival.
    Zhang W, Zhao C, Zhao J, Zhu Y, Weng X, Chen Q, Sun H, Mi JQ, Li J, Zhu J, Chen Z, Pandolfi PP, Chen S, Yan X, Xu J.
    Theranostics; 2018 Mar 12; 8(16):4359-4371. PubMed ID: 30214626
    [Abstract] [Full Text] [Related]

  • 9. MiR-495 is a tumor-suppressor microRNA down-regulated in MLL-rearranged leukemia.
    Jiang X, Huang H, Li Z, He C, Li Y, Chen P, Gurbuxani S, Arnovitz S, Hong GM, Price C, Ren H, Kunjamma RB, Neilly MB, Salat J, Wunderlich M, Slany RK, Zhang Y, Larson RA, Le Beau MM, Mulloy JC, Rowley JD, Chen J.
    Proc Natl Acad Sci U S A; 2012 Nov 20; 109(47):19397-402. PubMed ID: 23132946
    [Abstract] [Full Text] [Related]

  • 10. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
    Ye J, Zha J, Shi Y, Li Y, Yuan D, Chen Q, Lin F, Fang Z, Yu Y, Dai Y, Xu B.
    Clin Epigenetics; 2019 Oct 07; 11(1):137. PubMed ID: 31590682
    [Abstract] [Full Text] [Related]

  • 11. ZNF521 sustains the differentiation block in MLL-rearranged acute myeloid leukemia.
    Germano G, Morello G, Aveic S, Pinazza M, Minuzzo S, Frasson C, Persano L, Bonvini P, Viola G, Bresolin S, Tregnago C, Paganin M, Pigazzi M, Indraccolo S, Basso G.
    Oncotarget; 2017 Apr 18; 8(16):26129-26141. PubMed ID: 28412727
    [Abstract] [Full Text] [Related]

  • 12. Identification of MLL-fusion/MYC⊣miR-26⊣TET1 signaling circuit in MLL-rearranged leukemia.
    Huang H, Jiang X, Wang J, Li Y, Song CX, Chen P, Li S, Gurbuxani S, Arnovitz S, Wang Y, Weng H, Neilly MB, He C, Li Z, Chen J.
    Cancer Lett; 2016 Mar 28; 372(2):157-65. PubMed ID: 26791235
    [Abstract] [Full Text] [Related]

  • 13. The lncRNA LAMP5-AS1 drives leukemia cell stemness by directly modulating DOT1L methyltransferase activity in MLL leukemia.
    Wang WT, Chen TQ, Zeng ZC, Pan Q, Huang W, Han C, Fang K, Sun LY, Yang QQ, Wang D, Luo XQ, Sun YM, Chen YQ.
    J Hematol Oncol; 2020 Jun 17; 13(1):78. PubMed ID: 32552847
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Bortezomib suppresses self-renewal and leukemogenesis of leukemia stem cell by NF-ĸB-dependent inhibition of CDK6 in MLL-rearranged myeloid leukemia.
    Zhou B, Qin Y, Zhou J, Ruan J, Xiong F, Dong J, Huang X, Yu Z, Gao S.
    J Cell Mol Med; 2021 Mar 17; 25(6):3124-3135. PubMed ID: 33599085
    [Abstract] [Full Text] [Related]

  • 17. TGIF1 is a negative regulator of MLL-rearranged acute myeloid leukemia.
    Willer A, Jakobsen JS, Ohlsson E, Rapin N, Waage J, Billing M, Bullinger L, Karlsson S, Porse BT.
    Leukemia; 2015 May 17; 29(5):1018-31. PubMed ID: 25349154
    [Abstract] [Full Text] [Related]

  • 18. Essential role of PU.1 in maintenance of mixed lineage leukemia-associated leukemic stem cells.
    Aikawa Y, Yamagata K, Katsumoto T, Shima Y, Shino M, Stanley ER, Cleary ML, Akashi K, Tenen DG, Kitabayashi I.
    Cancer Sci; 2015 Mar 17; 106(3):227-36. PubMed ID: 25529853
    [Abstract] [Full Text] [Related]

  • 19. The PAF complex regulation of Prmt5 facilitates the progression and maintenance of MLL fusion leukemia.
    Serio J, Ropa J, Chen W, Mysliwski M, Saha N, Chen L, Wang J, Miao H, Cierpicki T, Grembecka J, Muntean AG.
    Oncogene; 2018 Jan 25; 37(4):450-460. PubMed ID: 28945229
    [Abstract] [Full Text] [Related]

  • 20. SETDB1 mediated histone H3 lysine 9 methylation suppresses MLL-fusion target expression and leukemic transformation.
    Ropa J, Saha N, Hu H, Peterson LF, Talpaz M, Muntean AG.
    Haematologica; 2020 Sep 01; 105(9):2273-2285. PubMed ID: 33054052
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 39.